首都医科大学附属北京天坛医院神经肿瘤综合治疗病区是在2018年10月医院搬迁至新院区后成立的新科室，是专门从事神经肿瘤综合治疗的，国内第一个独立病区，共设置普通医疗床位34张，研究型病房床位12张。主要针对胶质瘤、髓母细胞瘤、生殖细胞瘤、中枢神经系统淋巴瘤和脑转移瘤等脑与脊髓恶性肿瘤，开展化疗、靶向治疗、免疫疗法等综合治疗。研究病房用于临床试验治疗，主要开展Ⅰ-Ⅳ期药物临床试验和可穿戴医疗设备等临床试验研究，开展神经系统肿瘤的综合治疗临床研究。

病区配备医护人员29名，其中医生13名，护士16名。本学科有博士研究生导师3名硕士研究生导师1名，招收博（硕）士研究生和博士后研究学者。目前承担国家十三五新药创制重点项目2项，国家自然科学基金面上项目2项，北京市中医药管理局人才支撑项目1项，新药临床试验21项。

科室常规开设“神经外科——神经肿瘤综合诊疗”门诊，此外，联合神经外科专家、放疗科专家组成MDT团队，开设“脑胶质瘤综合治疗”会诊；联合神经内科专家和影像科专家开设“神经炎症与肿瘤鉴别”会诊。

学科成立以来，致力于将最先进的诊疗理念和技术提供给患者，先后与国际知名医疗中心专家学者开展临床及学术交流和远程会诊。合作专家包括：美国加州大学洛杉矶分校神经肿瘤科主任Timothy Cloughesy教授，美国M.D.安德森癌症中心神经肿瘤科名誉主席W.K.Alfred Yung教授、现任主任John de Groot教授，梅奥诊所神经肿瘤科专家Joon Uhm教授和Maciej Mrugala教授，美国德克萨斯大学休斯敦医学院Jay Zhu教授。

科室承办《医学参考报神经肿瘤频道》，传播神经肿瘤诊疗新技术和新进展，发布与国际同步的前沿学术信息。

科研课题：

1. 一项在难治/复发性胶质母细胞瘤患者中评估SNC-109 CAR-T细胞治疗的安全性、耐受性、药代动力学和抗肿瘤活性的Ⅰ期临床研究，2022.3-2025.3，项目编号：HX-A-2022007,项目负责人：李文斌，182.7027万（在研）

2. 基于细胞特征/联合药物-最优电场预测模型的TTfields治疗GBM策略优化研究，基于细胞特征/联合药物-最优电场预测模型的TTfields治疗GBM策略优化研究，2020.11-2023.10, 2020年京津冀合作项目，负责人，60万（在研）

3. 鞘内注射甲氨蝶呤联合全身化疗治疗胶质瘤脑脊液播散的前瞻性随机对照临床研究，2020.1-2022.12,首发2020-2-2048，2020年首度卫生发展科研专项，负责人，20万（在研）

4. 绿原酸通过IL10RA-JAK-STAT通路调节巨噬细胞计划治疗胶质瘤的分子机制研究，2020.1-2023.12，课题编号：81972338，国家自然科学基金，负责人，55万（在研）

5. 脑胶质瘤患者接受鞘内化疗的疗效及临床预后相关性研究，开始日期 ：2020-01-01，研究类型 ：基础研究，预算金额总计(万元)：100万，资助年限：5年，项目类型 ：天坛医院引进人才启动基金。项目来源 ：天坛医院引进人才启动基金，项目编号 RCYJ-2020-2025-LWB，负责人 ：李文斌，在研。

临床研究：

1. ASC40片联合贝伐珠单抗对照安慰剂联合贝伐珠单抗治疗复发胶质母细胞瘤患者的随机、双盲、多中心III期临床试验（CTR20212830）；ASC40-301；2021.11.16； PI，在研

2. 在晚期高级别脑胶质瘤患者中评价注射用重组人 PD- 1 抗体单纯疱疹病毒（rHSV-1-APD1）的安全性、生物分布和初步疗效的单臂、剂量爬坡的Ⅰ期临床研究（CTR20212368）； YST-02-102； 2021.9.18； PI， 在研

3. 评价KY100001片在晚期实体瘤患者中的安全性、耐受性、药代动力学、药效动力学及初步有效性的单臂、开放、单/多次给药剂量递增和剂量扩展的I期临床研究 (CTR20211073); KPC/KY100001/C101; 2021.8.27; PI, 在研

4. 多中心、随机、双盲、安慰剂对照、II期临床试验，评价CAN008与替莫唑胺在放射治疗期间以及放疗结束后合并使用治疗新诊断的胶质母细胞瘤患者的有效性和安全性(CTR20211888); CAN008-G-202; 2021.9.6; PI, 在研

5. 一项评价溶瘤病毒（OH2）注射液治疗中枢神经系统肿瘤复发后手术患者的安全性、耐受性及初步疗效的单臂、开放性、多中心临床研究（CTR20211817）；BH-OH2-015；2021. 8. 3；PI, 在研

6. 在新诊断为胶质母细胞瘤并且全新生物标记物DGM1阳性患者中评估Enzastaurin联合替莫唑胺同步放化疗加辅助化疗方案的随机双盲安慰剂对照III期临床试验(CTR20210055);DB102-01; 2021.6.18, PI, 在研

7. 评价SYHA1813口服溶液治疗复发或晚期实体瘤患者的安全性、耐受性、药代动力学特征和初步疗效的Ⅰ期临床试验（CTR20210775）；HA1814-202001/PRO;2021.5.7，PI，在研

8. 一项多中心、开放、单臂I期剂量探索和II期剂量扩展研究，评价FCN-159在1型神经纤维瘤病患者中的安全性、耐受性、药代动力学特征和初步抗肿瘤活性（CTR20202330）；FCN-159-002；2021.4.23，PI，在研

9. 评估GNC-039四特异性抗体注射液在复发/难治性或转移性实体瘤中的安全性、耐受性、药代动力学/药效动力学及抗肿瘤活性的开放性、多中心、I期临床研究（NCT04794972）；GNC-039-101；2021.3.26，PI, 在研

10. 评价HZ-A-018在原发或继发中枢神经系统淋巴瘤的安全性和有效性研究（CTR20210181）；HZ-A-018-102；2021.2.23，PI，在研

11. 一项随机、多中心、开放、阳性对照的评价ACT001单独使用和联合替莫唑胺对照替莫唑胺或洛莫司汀单独使用治疗复发脑胶质母细胞瘤的有效性和安全性的II期临床研究（CTR20202393）；ACT001-CN-002；2021.1.22，PI，在研

12. 一项在新诊断的胶质母细胞瘤完成标准同步放化疗（CCRT）后淋巴细胞减少的患者中评价TJ107疗效和安全性的随机、单盲、安慰剂对照Ⅱ期临床研究；（CTR20202070）； TJ107001GBM201,2020.12.31,，PI，在研

13. SDT-101马来酸盐胶囊在晚期恶性实体瘤患者中单次给药和多次连续给药的耐受性、药代动力学、剂量递增的安全性、初步疗效评价的I期临床试验（CTR20200177）； SDT—101—I—001；2020.11.12，PI，在研

14. 随机、对照、开放、多中心---评价可穿戴脑胶质瘤电场治疗仪联合替莫唑胺治疗复发胶质母细胞瘤（GBM）的安全性和有效性; (ChiCTR2000034285), PI, 2020.09，在研

15. 随机、对照、开放、多中心、Ⅱ/Ⅲ期临床研究评价注射用绿原酸治疗复发Ⅳ级胶质母细胞瘤（GBM）的安全性和有效性（CTR20160113），LYS-GBM-01，PI

16. 注射用和厚朴酚脂质体（HK）治疗晚期恶性实体瘤患者临床安全性、耐受性和药代动力学的I期临床试验（CTR2018L05330），PW/8675-001-3.0，PI

一、重要学术论文

1. Xun Kang#, Feng Chen, Shou-Bo Yang, Ya-Li Wang, Zeng-Hui Qian, Yan Li, Hao Lin, Parker Li, Yi-Chen Peng, Xiao-Min Wang, Wen-Bin Li*. Intrathecal methotrexate in combination with systemic chemotherapy in glioblastoma patients with leptomeningeal dissemination: A retrospective analysis.World Journal of Clinical Cases. 2022 March 24; 0(0): 0-0. (IF=1.534)

2. 林艺#, 王策, 康勋, 康庄，陈峰，江波，李文斌*．PTK7基因在脑胶质瘤中表达和临床预后的生物信息数据集分析[Ｊ]. 肿瘤预防与治疗, 2022, 35(3): 217-225

3. Shenglan Li#, Jinyi Chen, Yaqiong Fan, Ce Wang, Can Wang, Xiaohong Zheng, Feng Chen, Wenbin Li* . Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma. Signal Transduction and Targeted Therapy. 2022, 7(49)(IF=38.104)

4. Weichunbai Zhang#，Jing Jiang，Xinyi Li，Yongqi He, Feng Chen，Wenbin Li*. Dietary Factors and Risk of Glioma in Adults: A Systematic Review andDose-Response Meta-Analysis ofObservational Studies. Frontiers in Nutirtion. Feb 2022,  9: 1-14(IF=6.552)

5. 林艺#, 王策, 康勋, 康庄，陈峰, 江波, 李文斌*.胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析. 中国癌症杂志. 2022, 32(1):13-23.

6. 蔡泽豪#，郑晓红，王策，陈峰，李文斌*.基于2021年新版WHO中枢神经系统肿瘤分类的胶质母细胞瘤患者生存数据分析，北京医学. 2021.11.4,43（12）：1100-1103

7. 籍强#，黄安鹏，周莉莉，康勋，李文斌*. 影像组学助力原发性中枢神经系统淋巴瘤的精准诊断，北京医学. 2021.8.16，43（8）: 803-805

8. 郑晓红#，陈峰*，李文斌. 靶向治疗和免疫治疗时代下的原发性中枢神经系统淋巴瘤治疗进展，北京医学. 2021.8.16，43（8）: 806-809

9. 陈峰，李文斌*.开展临床研究,推动原发性中枢神经系统淋巴瘤规范化诊疗, 北京医学. 2021.8.16，43（8）: 800-802

10. 黄梦倩#，陈峰，康庄，王策，齐雪岭，董格红，郑晓红，李文斌*. 糖皮质激素影响原发性中枢神经系统淋巴瘤诊断 一例报告并文献复习，北京医学. 2021.8.16，43（8）: 810-813

11. Lili Zhou, Hong Peng, Qiang Ji, Bo Li, Lexin Pan, Feng Chen, Zishan Jiao, Yali Wang, Mengqian Huang, Gaifen Liu, Yaou Liu, Wenbin Li*. Radiomic signatures based on multiparametric MR images for predicting Ki-67 index expression in medulloblastoma. Annals of Translation Medicine. Nov, 2021, 9(22):1665. (IF=3.932)

12. Shenglan Li#, Long Li, Jinyi Chen, Yaqiong Fan, Ce Wang, Yuan Du, Caixia Guo*, Feng Chen, Wenbin Li*. Liposomal honokiol inhibits glioblastoma growth through regulating macrophage polarization. Annals of Translational Medicine.  2021;9(22):1644. (IF=3.932)

13. Xiaohong Zheng#, Parker Li, Qianqian Dong, Yihong Duan, Shoubo Yang, Zehao Cai, Feng Chen* and Wenbin Li*. MicroRNAs as Diagnostic Biomarkers in Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology. Sept 17, 2021; 11:12 (IF=6.244)

14. Botao Zhang, Quanyou Wu, Shujun Cheng*, Wenbin Li*.Systematic Profiling of mRNA Splicing Reveals the Prognostic Predictor and Potential Therapeutic Target for Glioblastoma Multiforme. Journal of Oncology. July 6, 2021. 2021:4664955 (IF=4.375)

15. Zehao Cai#, Chunna Yu, Shenglan Li, Can Wang, Yaqiong Fan, Qiang Ji, Feng Chen and Wenbin Li*. A Novel Classification of Glioma Subgroup, Which Is Highly Correlated With the Clinical Characteristics and Tumor Tissue Characteristics, Based on the Expression Levels of Gb and Gg Genes. Frontiers in Oncology. June 18, 2021; 11: 685823 (IF= 6.244)

16. Shenglan Li#, Jinyi Chen, Feng Chen, Ce Wang, Xiaodi Guo, Can Wang, Yaqiong Fan, Yali Wang, Yichen Peng, Wenbin Li *. Liposomal honokiol promotes hair growth via activating Wnt3a/β-catenin signaling pathway and down regulating TGF-β1 in C57BL/6N mice. Biomedicine & Pharmacotherapy. September 2021; 141:111793 (IF=6.529)

17. Zheng Yi#, Ji Qiang, Xie Lei, Wang Can, Yu ChunNa, Wang YaLi, Jiang Jing, Chen Feng*, Li Wenbin*. Ferroptosis-related gene signature as a prognostic marker for lower-grade gliomas. J Cell Mol Med. 2021 Feb; 25(6):3080-90 (IF=5.31)

18. Shenglan Li#, Wei Li, Gang Chen, Jing Huang, Wenbin Li*. MiRNA-27a-3p induces temozolomide resistance in glioma by inhibiting NF1 level. Am J Transl Res. 15 August 2020, 12(8):4749-4756 (IF= 3.266)

19. Xiu Liu#, Chunyan Song#, Shoubo Yang, Qiang Ji, Feng Chen*, Wenbin Li*. IFI30 expression is an independent unfavourable prognostic factor in glioma. Journal of Cellular and Molecular Medicine. 28 September 2020, 24:18. (IF= 4.658)

20. Lulu Hu#, Dachuan Shen#, Dapeng Liang#, Ji Shi#, Chunyan Song, Ke Jiang, Menglin Ren, Sha Du, Wei Cheng, Jianmei Ma, Shao Li, Xiaolin Bi, Martin P. Barr, Zhiyou Fang, Qing Xu , Wenbin Li, Haozhe Piao, Songshu Meng*, Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth. Cancer Letter. 28 Novemer 2020. 493:156-166 (IF= 6.508)

21. Yan Li, Shoubo Yang, Chengcheng Hao, Janxin Chen, Shan Li, Zhuang Kang, Xun Kang, Hongmei Zhang, Wenbin Li*. Effect of BRAF/MEK Inhibition on Epithelioid Glioblastoma with BRAFV600E Mutation: a Case Report and Review of the Literature. Clinical Laboratory. 2020. 66:1629-1633. (IF= 0.955)

22. Xiaohong Zheng#, Xiyou Zhang#, Qianqian Dong, Feng Chen*, Shoubo Yang, Wenbin Li. Efficacy and safety of chimeric antigen receptor-T cells in the treatment of B cell lymphoma: a systematic review and meta-analysis. Chinese Medical Journal (Engl). 2020, 133(1): 74-85. (IF= 1.555)

23. Xiaohong Zheng#, Shoubo Yang#, Feng Chen*, Si Wu and Wenbin Li*. The Efficacy and Safety of Cytarabine on Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis. Frontier in Oncology. 2020 July 31. 10:1213 (IF= 4.137)

24. Botao Zhang, Yuanjing Wang, Hongxia Li, Lin Feng*, Wenbin Li*, Shujun Cheng*. Identification of Prognostic Biomarkers for Multiple Solid Tumors Using a Human Villi Development Model. Frontiers in Cell and Development Biology. 2020 June; 8:492. (IF= 5.206)

25. Xiu Liu, Feng Chen*, Wenbin Li*. Elevated expression of DOK3 indicates high suppressive immune cell infiltration and unfavorable prognosis of gliomas. International Immunopharmacology. 2020 June; 83: 106400. (IF=3.361)

26. Chengcheng Hao#, Gang Chen#, Huishan Zhao, Yan Li, Jianxin Chen, Hongmei Zhang, Shan Li, Yuze Zhao, Feng Chen, Wenbin Li *， Wen G. Jiang*. PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis. Frontier in Oncology. 24 June 2020, 10:1015. (IF= 4.137)

27. Zehao Cai#, Shoubo Yang, Xiaoyan Li, Feng Chen and Wenbin Li*.Viral infection and glioma: a meta-analysis of prognosis. BMC Cancer., June 12 2020, 20:549 (IF=2.933)

28. 边伟帅, 李文斌*, 康勋, 陈建新, 陈炜. 低频磁疗对缓解脑胶质瘤患者瘤周水肿的效果初探, 上海预防医学，2020，32（1）: 89-93

29. 李文斌, 康勋. MDT在我国脑胶质瘤诊疗方面的开展情况. 中华医学信息导报. 2020，35（22）：5

30. Jie-Lin Zhang#, Xiao-Song Zhong, Shou-Bo Yang, Xun Kang, Yan Li, Jian-Xin Chen, Wen-Bin Li*. Features and therapeutic potential of T-cell receptors in high-grade Glioma. Chinese Medical Journal. 2019;132(12): 1435-1440 (IF= 1.555)

31. Chengcheng Hao#, Yuxin Cui#, Siyuan Chang#, Jing Huang, Emily Birkin, Mu Hu, Xiuyi Zhi, Wenbin Li, Lijian Zhang, Shan Cheng* & Wen G. Jiang*. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase. Scientific Reports. 2019, 9:18101  (IF= 4.011)

32. Shuli Liang#, Xing Fan#, Ming Zhao, Xia Shan, Wenling Li, Ping Ding, Gan You, Zhen Hong, Xuejun Yang, Guoming Luan, Wenbin Ma, Hui Yang, Yongpin You, Tianming Yang, Liang Li, Weiping Liao, Lei Wang, Xun Wu, Xinguang Yu, Jianguo Zhang, Qing Mao, Yuping Wang, Wenbin Li, Xuefeng Wang, Chuanlu Jiang, Xiaoyan Liu, Songtao Qi, Xingzhou Liu, Yan Qu, Jiwen Xu, Weimin Wang, Zhi Song, Jinsong Wu, Zhixiong Liu, Ling Chen, Yuanxiang Lin, Jian Zhou, Xianzeng Liu, Wei Zhang, Shichuo Li*, Tao Jiang*. Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy. Cancer Medicine. 2019 August 28. 8(10): 4527-4535 (IF= 3.357)

33. Shuai Huang#, Lu-Lu Wang#, Ni-Na Xue, Cong Li, Hui-Hui Guo, Tian-Kun Ren, Yun Zhan, Wen-Bing Li, Jie Zhang, Xiao-Guang Chen, Yan-Xing Han*, Jin-Lan Zhang*, Jian-Dong Jiang*. Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation, Theranostics. 2019, 9(23): 6745-6763 (IF= 8.063)

34. Qian Z#,Li Y#,Wang Y,Li L,Li R,Wang K,Li S,Tang K,Zhang C,Fan X,Chen B*,Li W*.Differentiation of glioblastoma from solitary brain metastases using radiomic machine-learning classifiers. Cancer Letters. 2019 Jun 1;451:128-135 (IF= 6.508)

35. Yang Shoubo#, Gao Kaidi#, Li Wenbin*. Identification of hub genes and pathways in glioblastoma by bioinformatics analysis. Oncol Lett. 2019 Jan;17(1):1035-1041.

36. 康勋#, 蔡泽豪, 杨守博, 李文斌*. 高级别脑干胶质瘤同步放化疗疗效及影响因素. 中国肿瘤临床. 2019, 46(18): 930-933

37. 康勋，李文斌*. 脑胶质瘤诊疗规范关于药物治疗的解读. 海南医学. 2019, 30(15): 1905-1908

38. 陈峰, 郑晓红, 李文斌*. 脑胶质瘤免疫治疗进展. 首都医科大学学报. 2019, 40(6): 966－971

39. 蔡泽豪, 康勋, 李晓燕, 陈峰, 李文斌*. 肿瘤治疗电场在脑胶质母细胞瘤治疗中的现状与前景. 中国肿瘤临床. 2019, 46(24): 1247-1250

40. 康勋，张锡友，陈 峰，李丹丹，董倩倩，宋清坤，钟晓松，李文斌*. CAR-T治疗B细胞淋巴瘤不良反应的Meta分析. 中国癌症杂志. 2019, 29(8):568-575

41. 刘龙#，李文斌，杨彩霞，王进，李岩，漆璐，陈建新，陈刚，王泽娟，闯冬梅，刘英，雷春璞，刘晓娜，王瑜，王兴河*. 替莫唑胺胶囊在中国高级别胶质瘤患者中的生物等效性研究. 中国临床药理学杂志. 2019, 35(9): 858-868

42. 于春娜#, 江波, 李文斌*, 陈峰. β －羟丁酸对脑胶质瘤细胞增生糖酵解的影响. 首都医科大学学报. 2019, 40(2): 186-190

43. Kang Zhuang#, Yang Shoubo, Zhang Hongmei, Zhou Quan, Chen Jianxin, Li Yan, Kang Xun, Li Shan, Li Wenbin*. Extracranial metastasis of anaplastic oligoastrocytoma. Cancer Biol Med. 2018 Aug;15(3):311-313 (IF=4.467)

44. Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF7, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network, Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018 Feb 15; 24(4):737-743   (IF=8.911)

45. Shuai Jin#, Zenghui Qian#, Tingyu Liang, Jingshan Liang, Fuqiang Yang, Lihua Sun, Wenbin Li, Xiaoguang Qiu, Man Zhang*. Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma. World Neurosurgery. 2018, 117:e34-e41 (IF=1.829)

46. Huimin Hu, Quanhua Mu, Zhaoshi Bao, Yiyun Chen, Yanwei Liu, Jing Chen, Kuanyu Wang, Zheng Zhao, Yoonhee Nam, Biaobin Jiang, Jason K. Hee-Jin Cho, Nam-Gu Her, Chuanbao Zhang, Ying Zhang, Fan Zeng, Fan Wu, Xun Kang, Yuqing Liu, Zenghui Qian, Zhiliang Wang, Ruoyu Huang, Qiangwei Wang, Wei Zhang, Xiaoguang Qiu, Wenbin Li, Do-Hyun Nam, Xiaolong Fan*, Jiguang Wang*, Tao Jiang*, Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018, Nov 29;175(6):1665-1678

47. 陈建新#，康勋，李岩，李珊，康庄，李文斌*. 脑脊液D-二聚体评估胶质瘤脑室侵犯和脊髓播散的临床意义. 中国癌症杂志. 2018,28（9）：641-648

48. 杨靖怡#，杨守博，康庄，康勋，李文斌*. 绿原酸在脑胶质瘤治疗中的应用前景. 中国肿瘤临床. 2018,45(5): 256-259

49. 白玥#，钟晓松，李文斌*. 甲氨蝶呤通过RAS/MAPK/ERK/MYC/CD47 信号通路抑制胶质母细胞瘤的生长. 肿瘤代谢与营养电子杂志. 2018, 5(2): 144-150

50. 陈刚#，王进，王泽娟，孔小轶，刘晓娜，刘晨，刘英，漆璐，周保利，李文斌，王兴河*. 液质联用测定血浆替莫唑胺的浓度. 中国临床药理学杂志. 2018, 34(9): 1111-1114

51. 闯冬梅#，李岩，刘俐惠*，李文斌*. EAT-10 在高级别脑胶质瘤患者中应用的意义. 肿瘤代谢与营养电子杂志. 2018, 5(1): 84-87

52. Tiankun Ren, Yanan Wang, Caihong Wang, Mengtian Zhang, Wang Huang, Jiandong Jiang, Wenbin Li*, Jinlan Zhang. Isolation and identification of human metabolites from a novel anti-tumor candidate drug 5-chlorogenic acid injection by HPLC-HRMS/MSn and HPLC-SPE-NMR. Analytical and Bioanalytical Chemistry. 2017, 409: 7035–7048 (IF= 3.286)

53. Kai-Hong Zhao#, Xun Kang, Xiao-shong Zhong, Wen-bin Li*, Antiglioma effects of cytarabine on leptomeningeal metastasis of high-grade glioma by targeting the PI3K/Akt/m-TOR pathway. Drug Design  Development and Therapy, 2017, 11:1905-1915(IF=3.208)

54. Shou-Bo Yang#, Kai-Di Gao, Tao Jiang, Shu-Jun Cheng, Wen-Bin Li*, Bevcizumab combined with chemotherapy for glioblastoma:a meta-analysis of randomized controlled trials. Oncotarget. 2017, 8 (34): 57337-57344 (IF =3.046)

55. Nina Xue, Qin Zhou, Ming Ji, Jing Jin, Fangfang Lai, Ju Chen, Mengtian Zhang, Jing Jia, Huarong Yang, Jie Zhang, Wenbin Li, Jiandong Jiang,  Xiaoguang Chen. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Scientific Reports. 2017, 7:39011 (IF= 4.011)

56. 白玥#，钟晓松，李文斌*. 嵌合抗原受体T细胞治疗多形性胶质母细胞瘤的最新进展. 中国肿瘤临床. 2017,44（16）：794-799

57. 王进#，陈刚，孔小轶， 李岩，王泽娟，刘英， 漆璐，刘晨，刘晓娜， 雷春璞，冯丽，王瑜， 周保利，李文斌，王兴河*. 单次静脉输注注射用替莫唑胺在中国脑胶质瘤患者和健康受试者的药代动力学研究. 中国临床药理学杂志. 2017,33（23）：2416-2419

58. 李珊#，李文斌*. 25例成人丘脑恶性神经胶质瘤临床特点分析. 南京医科大学学报（自然科学版）. 2017,37（10）：1320-1326

59. 李文斌，康勋, 张红梅，陈建新  Wen Patrick Yung，江涛*，高级别胶质瘤治疗反应，中华神经外科杂志，2017,33（3）：304-307

二、指南编写

1. Tao Jiang*, Do-Hyun Nam*, Zvi Ram*, Wai-sang Poon*, Jiguang Wang*, Damdindorj Boldbaatar*, Ying Mao*, Wenbin Ma*, Qing Mao*, Yongping You*, Chuanlu Jiang*, Xuejun Yang*, Chunsheng Kang, Xiaoguang Qiu, Wenbin Li, Shaowu Li, Ling Chen, Xuejun Li, Zhixiong Liu, Weimin Wang, Hongmin Bai, Yu Yao, Shouwei Li, Anhua Wu, Ke Sai, Guilin Li, Kun Yao, Xinting Wei, Xianzhi Liu, Zhiwen Zhang, Yiwu Dai, Shengqing Lv, Liang Wang, Zhixiong Lin, Jun Dong, Guozheng Xu, Xiaodong Ma, Wei Zhang, Chuanbao Zhang, Baoshi Chen, Gan You, Yongzhi Wang, Yinyan Wang, Zhaoshi Bao, Pei Yang, Xing Fan, Xing Liu, Zheng Zhao, Zheng Wang, Yiming L, Zhiliang Wang, Guanzhang Li, Shengyu Fang, Lianwang Li, Yanwei Liu, Shuai Liu, Xia Shan, Yuqing Liu, Ruichao Chai, Huimin Hu, Jing Chen, Wei Yan, Jinquan Cai, Hongjun Wang, Lingchao Chen, Yuan Yang, Yu Wang, Lei Han, Qixue Wang, on behalf of the Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology. Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters. 2021, 499: 60-72 (IF=6.508)

2. Shuli Liang#, Xing Fan#, Ming Zhao, Xia Shan, Wenling Li, Ping Ding, Gan You, Zhen Hong, Xuejun Yang, Guoming Luan, Wenbin Ma, Hui Yang, Yongpin You, Tianming Yang, Liang Li, Weiping Liao, Lei Wang, Xun Wu, Xinguang Yu, Jianguo Zhang, Qing Mao, Yuping Wang, Wenbin Li, Xuefeng Wang, Chuanlu Jiang, Xiaoyan Liu, Songtao Qi, Xingzhou Liu, Yan Qu, Jiwen Xu, Weimin Wang, Zhi Song, Jinsong Wu, Zhixiong Liu, Ling Chen, Yuanxiang Lin, Jian Zhou, Xianzeng Liu, Wei Zhang, Shichuo Li*, Tao Jiang*. Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy. Cancer Medicine. 2019 August 28. 8(10): 4527-4535

3. 江涛，李文斌 等，国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版).中华神经外科杂志. 2019,35(3): 217-239.

4. Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, Qiu X, Wang W, Li W, Yao Y, Li S, Li S, Wu A, Sai K, Bai H, Li G, Chen B, Yao K, Wei X, Liu X, Zhang Z, Dai Y, Lv S, Wang L, Lin Z, Dong J, Xu G, Ma X, Cai J, Zhang W, Wang H, Chen L, Zhang C, Yang P, Yan W, Liu Z, Hu H, Chen J, Liu Y, Yang Y, Wang Z, Wang Z, Wang Y, You G, Han L, Bao Z, Liu Y, Wang Y, Fan X, Liu S, Liu X, Wang Y, Wang Q. CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Letters.2016 Jun 1; 375(2): 263-73. (sci= 5.99)

三、重要奖项

1. 脑胶质瘤诊疗技术的研发和创新药物临床试验 获2019年北京医学科技奖 二等奖 20200706

2. 脑胶质瘤诊疗关键技术创新与推广应用  国家科学技术进步奖 二等奖 20171206